肝细胞癌微血管侵犯的肿瘤灶与肿瘤包膜空间转录组-代谢特征:空间多组学研究
该研究整合空间转录组学与空间代谢组学,分析4例患者6份组织样本(含2例MVI+、2例MVI-和2例癌旁组织),并结合79例公共单细胞RNA测序数据。在MVI+肝细胞癌肿瘤灶中鉴定出STMN1+HMGN2+GPC3+恶性细胞亚型,其增殖活性增强且与不良预后相关,并在79例本地队列中经多重免疫荧光验证(p=0.046)。肿瘤包膜中iCAFs相关基因在MVI+病例中下调,牛磺酸通过抑制iCAF活性促进肝癌增殖和迁移。
要点
- MVI+肝细胞癌肿瘤灶富集STMN1+HMGN2+GPC3+恶性细胞亚型,增殖增强且预后差。
- 该亚型呈甘油酯代谢受抑的代谢重编程特征。
- 肿瘤包膜牛磺酸通过抑制iCAF活性促进肝癌增殖和迁移。
核心结论
- MVI+肝细胞癌肿瘤灶存在高增殖且代谢重编程的恶性细胞亚型,肿瘤包膜牛磺酸调控iCAF活性影响肿瘤进展。
研究设计与样本
- 对4例患者6份组织样本(2例MVI+、2例MVI-、2例癌旁)行空间转录组和空间代谢组检测,整合79例公共单细胞RNA测序数据。
- 以患者身份为协变量进行区域差异表达基因分析,并在79例患者中行多重免疫荧光验证。
- 外部验证采用TCGA-LIHC队列(n=299)和独立微阵列数据集(n=62)。
- 体外功能验证使用肝星状细胞来源的iCAFs和原代CAFs共培养模型评估增殖、迁移和侵袭。
主要发现
- 肿瘤灶中鉴定出MVI+肝细胞癌富集的STMN1+HMGN2+GPC3+恶性细胞亚型,增殖活性增强且与不良预后相关。
- 79例本地队列多重免疫荧光显示三个基因在MVI+组表达显著高于MVI-组(p=0.046)。
- 该细胞群呈甘油酯代谢受抑的代谢重编程特征。
- 肿瘤包膜中iCAFs相关基因在MVI+病例中下调,iCAFs位于远离肿瘤边界处。
- 空间代谢物映射显示牛磺酸与iCAFs强相关,功能实验表明牛磺酸通过抑制iCAF活性促进肝癌增殖和迁移。
临床怎么用
- STMN1、HMGN2和GPC3三重免疫荧光染色可作为MVI+肝细胞癌的潜在识别标志。
- 靶向牛磺酸-iCAF轴可能为MVI+肝细胞癌提供治疗干预方向。
局限性
- 空间组学数据样本量小,限制了对STMN1+HMGN2+GPC3+细胞亚型和iCAFs更完整的分子功能分析。
- 需更大规模空间转录组队列进一步验证和拓展研究结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Microvascular invasion (MVI) is closely related to the recurrence and metastasis of hepatocellular carcinoma (HCC), but the underlying cellular mechanism remains largely elusive. This study aims to elucidate the regional cellular discrepancy between MVI-positive (MVI+) and MVI-negative (MVI-) HCC by integrating Spatial transcriptomics (ST) and spatial metabolomics (SM). METHODS AND FINDINGS: ST and SM were performed on six tissue samples from four patients (including 2 MVI+, 2 MVI-, and 2 paratumor tissues), with the integration of 79 public single-cell RNA sequencing datasets of HCC. Patient identity was used as a covariate in the linear equation for regional differentially expressed gene analysis with the ST data. Clinical validation was conducted through multiplex immunofluorescence staining in 79 patients, together with external validation in the cancer genome atlas (TCGA)-liver hepatocellular carcinoma (LIHC) cohort (n = 299) and an independent microarray dataset (n = 62). For cell-type-specific metabolic profiling, spatial transcriptomic-metabolic registration was performed. The functional roles of key metabolites were further validated in vitro using inflammatory cancer-associated fibroblasts (iCAFs) derived from hepatic stellate cells (HSCs) and primary CAFs through co-culture models and various functional assays assessing cell proliferation, migration, and invasion. In the tumor lesion, a malignant STMN1+HMGN2+GPC3+ cell subtype enriched in MVI+ HCC was identified, which exhibited enhanced proliferative activity and was associated with poor prognosis. This finding was further confirmed in a local cohort of 79 patients, where multiplex immunofluorescence staining for the three genes (STMN1, HMGN2, and GPC3) showed significantly higher expression in the MVI+ group than in the MVI- group (p = 0.046). Integrated SM analysis further revealed that this cell population underwent metabolic reprogramming characterized by suppressed glycerolipid metabolism. In the tumor capsule, iCAFs-related genes were downregulated in MVI+ cases, and iCAFs were located distally from the tumor boundary. Spatial metabolite mapping showed a strong correlation between taurine and iCAFs, and functional assays demonstrated that taurine promotes HCC proliferation and migration by suppressing iCAF activity. One limitation of this study is the small sample size of spatial omics data, which hinders a more complete molecular functional analysis of the STMN1+HMGN2+GPC3+ cell subtype and iCAFs in MVI+ HCC. Larger-scale ST cohorts are required to further validate and expand the findings of this study. CONCLUSIONS: This integrative spatial atlas proposes a hypothesis that there exists a highly proliferative and metabolically reprogrammed malignant cell subtype in the tumor lesion of MVI+ HCC, and that taurine in the tumor capsule modulates iCAF activity to influence tumor progression. The exploratory results provide mechanistic insights into MVI-related HCC progression and offer potential avenues for targeted therapeutic intervention of MVI+ HCC.
引用
- Luo ZH, Wang N, Zhao J, et al. Spatial transcriptomic-metabolic features of tumor foci and tumor capsule in microvascular invasion with hepatocellular carcinoma: A spatial multi-omics study. PLoS Med. 2026. PMID: 42139279. doi:10.1371/journal.pmed.1004703
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。